Cargando…
PARP Inhibitors in Endometrial Cancer: Current Status and Perspectives
Advanced, recurrent and metastatic endometrial cancer (EC) has a dismal prognosis due to poor response rates to conventional treatments. In the era of precision medicine, the improved understanding of cancer genetics and molecular biology has led to the development of targeted therapies, such as pol...
Autores principales: | Musacchio, Lucia, Caruso, Giuseppe, Pisano, Carmela, Cecere, Sabrina Chiara, Di Napoli, Marilena, Attademo, Laura, Tambaro, Rosa, Russo, Daniela, Califano, Daniela, Palaia, Innocenza, Muzii, Ludovico, Benedetti Panici, Pierluigi, Pignata, Sandro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7383016/ https://www.ncbi.nlm.nih.gov/pubmed/32801862 http://dx.doi.org/10.2147/CMAR.S221001 |
Ejemplares similares
-
Immune Checkpoint Inhibitors: A Promising Choice for Endometrial Cancer Patients?
por: Musacchio, Lucia, et al.
Publicado: (2020) -
Immunotherapy of Ovarian Cancer: The Role of Checkpoint Inhibitors
por: De Felice, Francesca, et al.
Publicado: (2015) -
Systematic lymph node dissection during interval debulking surgery for advanced epithelial ovarian cancer: a systematic review and meta-analysis
por: Caruso, Giuseppe, et al.
Publicado: (2022) -
Cabergoline as an adjuvant to standard heart failure treatment in peripartum cardiomyopathy: A case report and review of the literature
por: Caruso, Giuseppe, et al.
Publicado: (2020) -
Targeting immunometabolism mediated by the IDO1 Pathway: A new mechanism of immune resistance in endometrial cancer
por: Passarelli, Anna, et al.
Publicado: (2022)